Revi System
Urge Urinary Incontinence / Overactive Bladder
CommercialApproved (FDA De Novo 2023)
Key Facts
Indication
Urge Urinary Incontinence / Overactive Bladder
Phase
Commercial
Status
Approved (FDA De Novo 2023)
Company
About BlueWind Medical
BlueWind Medical commercial an implantable tibial neuromodulation device (Revi) for drug‑free treatment of urge urinary incontinence.
View full company profile